JP2015501832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501832A5 JP2015501832A5 JP2014546665A JP2014546665A JP2015501832A5 JP 2015501832 A5 JP2015501832 A5 JP 2015501832A5 JP 2014546665 A JP2014546665 A JP 2014546665A JP 2014546665 A JP2014546665 A JP 2014546665A JP 2015501832 A5 JP2015501832 A5 JP 2015501832A5
- Authority
- JP
- Japan
- Prior art keywords
- ghrelin
- subject
- use according
- polypeptide
- overeating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 15
- 101800001586 Ghrelin Proteins 0.000 claims 8
- 102400000442 Ghrelin-28 Human genes 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 235000020830 overeating Nutrition 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576217P | 2011-12-15 | 2011-12-15 | |
| US61/576,217 | 2011-12-15 | ||
| PCT/IB2012/002867 WO2013088241A1 (en) | 2011-12-15 | 2012-12-14 | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501832A JP2015501832A (ja) | 2015-01-19 |
| JP2015501832A5 true JP2015501832A5 (https=) | 2016-02-04 |
| JP6031121B2 JP6031121B2 (ja) | 2016-11-24 |
Family
ID=47780096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546665A Expired - Fee Related JP6031121B2 (ja) | 2011-12-15 | 2012-12-14 | 非アシル化グレリンを使用したグレリンレベル及びグレリン／非アシル化グレリン比の調節 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9550821B2 (https=) |
| EP (1) | EP2790721B8 (https=) |
| JP (1) | JP6031121B2 (https=) |
| CA (1) | CA2857276A1 (https=) |
| CY (1) | CY1121296T1 (https=) |
| DK (1) | DK2790721T3 (https=) |
| ES (1) | ES2705499T3 (https=) |
| HR (1) | HRP20190062T1 (https=) |
| HU (1) | HUE042102T2 (https=) |
| LT (1) | LT2790721T (https=) |
| PL (1) | PL2790721T3 (https=) |
| PT (1) | PT2790721T (https=) |
| RS (1) | RS58237B1 (https=) |
| SI (1) | SI2790721T1 (https=) |
| TR (1) | TR201900438T4 (https=) |
| WO (1) | WO2013088241A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190062T1 (hr) | 2011-12-15 | 2019-03-08 | Millendo Therapeutics Sas | Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma |
| EP3010529B1 (en) | 2013-06-21 | 2020-05-06 | Millendo Therapeutics SAS | Use of unacylated ghrelin, fragments and analogs thereof as antioxidant |
| EP3193939A4 (en) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| KR102323613B1 (ko) * | 2014-11-14 | 2021-11-09 | 에센셜리스 인코포레이티드 | 프라더-윌리 증후군 또는 스미스-마제니스 증후군을 가지는 대상체를 치료하는 방법 |
| US10053693B2 (en) | 2016-01-19 | 2018-08-21 | Mubin I. Syed | Method for controlling obesity using minimally invasive means |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| US6627729B1 (en) | 1997-03-24 | 2003-09-30 | Zymogenetics, Inc. | TML peptides |
| AU6515499A (en) | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| AU2001228325A1 (en) | 2000-02-01 | 2001-08-14 | Novo-Nordisk A/S | Use of compounds for the regulation of food intake |
| AU2001259056A1 (en) | 2000-05-17 | 2001-11-26 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
| WO2002060472A1 (fr) | 2001-01-31 | 2002-08-08 | Chugai Seiyaku Kabushiki Kaisha | Remedes pour des etats d'hyponutrition |
| WO2002060477A1 (en) | 2001-01-31 | 2002-08-08 | Human Genome Sciences, Inc. | Scaffolded fusion polypeptides, compositions for making the same and methods of using the same |
| US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| CA2470235C (en) | 2001-12-18 | 2012-02-07 | Theratechnologies Inc. | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| WO2003097083A1 (en) | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Medicinal compositions containing ghrelin |
| CA2543507C (en) | 2003-10-24 | 2012-05-01 | Theratechnologies Inc. | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions |
| EP1812044A2 (en) | 2004-10-27 | 2007-08-01 | Gastrotech Pharma A/S | Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure |
| JP5147827B2 (ja) | 2006-03-28 | 2013-02-20 | リアット・ミンツ | 高コレステロール血症および／または高コレステロールおよび／または高コレステロール関連疾患および／または脂血症および／または脂血症関連疾患および／または冠動脈疾患および／または体重管理および／または糖尿病および／または高血糖の治療のためのグレリンスプライス変種の使用 |
| US8318664B2 (en) * | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
| AU2008257448B9 (en) * | 2007-05-31 | 2013-07-11 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
| EP2067481A1 (en) * | 2007-12-03 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Therapeutic use of desacyl ghrelin |
| US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| HRP20190062T1 (hr) | 2011-12-15 | 2019-03-08 | Millendo Therapeutics Sas | Fragmenti neaciliranog grelina za uporabu u liječenju prader-willi sindroma |
-
2012
- 2012-12-14 HR HRP20190062TT patent/HRP20190062T1/hr unknown
- 2012-12-14 PT PT12829142T patent/PT2790721T/pt unknown
- 2012-12-14 LT LTEP12829142.4T patent/LT2790721T/lt unknown
- 2012-12-14 US US13/715,550 patent/US9550821B2/en not_active Expired - Fee Related
- 2012-12-14 US US14/364,228 patent/US20140336109A1/en not_active Abandoned
- 2012-12-14 EP EP12829142.4A patent/EP2790721B8/en active Active
- 2012-12-14 JP JP2014546665A patent/JP6031121B2/ja not_active Expired - Fee Related
- 2012-12-14 ES ES12829142T patent/ES2705499T3/es active Active
- 2012-12-14 CA CA2857276A patent/CA2857276A1/en not_active Abandoned
- 2012-12-14 HU HUE12829142A patent/HUE042102T2/hu unknown
- 2012-12-14 SI SI201231504T patent/SI2790721T1/sl unknown
- 2012-12-14 DK DK12829142.4T patent/DK2790721T3/en active
- 2012-12-14 RS RS20190033A patent/RS58237B1/sr unknown
- 2012-12-14 WO PCT/IB2012/002867 patent/WO2013088241A1/en not_active Ceased
- 2012-12-14 TR TR2019/00438T patent/TR201900438T4/tr unknown
- 2012-12-14 PL PL12829142T patent/PL2790721T3/pl unknown
-
2019
- 2019-01-14 CY CY20191100034T patent/CY1121296T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| JP2015501832A5 (https=) | ||
| EP3434687A3 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
| TN2012000215A1 (en) | Pharmaceutical compositions comprising a g l p -1 agonist and methionine | |
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| JP2010059183A5 (https=) | ||
| MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| WO2012165915A3 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
| JP2013509429A5 (https=) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| JP2018505158A5 (https=) | ||
| WO2009039982A3 (en) | Use of gip alone or in combination with dynorphin b as a therapeutic agent | |
| FI4374873T3 (fi) | Aine käytettäväksi silmäsairauksien hoidossa tai ehkäisyssä | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| JP2015518818A5 (https=) | ||
| JP2015517488A5 (https=) | ||
| WO2007108990A3 (en) | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation | |
| JP2012193216A5 (https=) | ||
| JP2013543899A5 (https=) | ||
| WO2013003449A3 (en) | Methods of treatment with glp-1 receptor agonists | |
| JP2014503593A5 (https=) | ||
| WO2007126363A8 (en) | Antisecretory protein for use in the treatment of compartment syndrome | |
| JP2016539156A5 (https=) | ||
| RU2016101064A (ru) | Состав с постоянным соотношением инсулина гларгина/ликсизенатида |